Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $19.04 USD
Change Today +0.14 / 0.74%
Volume 284.4K
QDEL On Other Exchanges
As of 5:20 PM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/8/15 - $29.38
52 Week Low
08/25/15 - $18.23
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QUIDEL CORP (QDEL)

Related News

No related news articles were found.

quidel corp (QDEL) Related Businessweek News

No Related Businessweek News Found

quidel corp (QDEL) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company offers Sofia analyzer, a fluorescent immunoassay system for hospitals, medical centers, and small clinics; various molecular assays, which run on thermocyclers; Sofia influenza A+B and QuickVue influenza tests for the detection of the viral antigens of influenza type A and B; and Sofia strep A fluorescent immunoassay and QuickVue Strep A tests for the detection of group A Streptococcal antigen from throat swabs. It also provides Sofia Respiratory Syncytial Virus (RSV) and QuickVue RSV tests for respiratory syncytial virus; cell culture and DFA detection solutions for the detection of various viral respiratory pathogens; and various traditional cell lines, specimen collection devices, media, and controls for the use in laboratories. In addition, the company offers ELVIS HSV, a cell culture system for the isolation and detection of herpes simplex virus types 1 and 2; and multiplex cell culture solution. Further, it provides Quidel Molecular Direct clostridium difficile assay; Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests, which are used for the detection of hCG in serum or urine for the early detection of pregnancy; Thyretain for the differential diagnosis of Graves disease; and QuickVue Chlamydia test for the detection of Chlamydia trachomatis. Additionally, the company offers QuickVue test, a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; serological test that measures antibodies circulating in the blood; and diagnostic and research products for oncology, bone health, and autoimmune diseases. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

610 Employees
Last Reported Date: 02/24/15
Founded in 1979

quidel corp (QDEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $524.4K
Chief Financial Officer
Total Annual Compensation: $331.9K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $297.5K
Senior Vice President of Research and Develop...
Total Annual Compensation: $195.5K
Senior Vice President of Business Development...
Total Annual Compensation: $334.3K
Compensation as of Fiscal Year 2014.

quidel corp (QDEL) Key Developments

Quidel Corp. Announces Board Changes

Quidel Corp. reported that Mark A. Pulido has resigned as Chairman of the company's Board of Directors, and notified the Board that he will not stand for re-election at the 2016 Annual Meeting of Shareholders. Current Board member, Kenneth F. Buechler has been appointed Chairman of the Board, effective immediately.

Quidel Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Tax Rate Guidance for the Full Year 2015

Quidel Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of USD 34,873,000 compared to USD 31,488,000 a year ago. Operating loss was USD 9,825,000 compared to USD 9,985,000 a year ago. Loss before income tax was USD 12,886,000 compared to USD 10,357,000 a year ago. Net loss was USD 8,931,000 or USD 0.26 per basic and diluted share compared to USD 6,908,000 or USD 0.20 per basic and diluted share a year ago. Adjusted net loss was USD 4,822,000 or USD 0.14 per share compared to USD 3,426,000 or USD 0.10 per share a year ago The increase in revenues in the second quarter of 2015 was due primarily to greater Sofia assay sales, followed by increased molecular and Graves' Disease product sales. The net loss increase in the second quarter of 2015 was mostly due to an increase in interest expense of USD 1.9 million after tax, or USD 0.05 per share, the result of the company's convertible debt offering in December 2014. For the six months, the company reported total revenues of USD 96,175,000 compared to USD 78,161,000 a year ago. Operating loss was USD 1,136,000 compared to USD 12,002,000 a year ago. Loss before income tax was USD 7,092,000 compared to USD 12,733,000 a year ago. Net loss was USD 4,940,000 or USD 0.14 per diluted share compared to net loss of USD 8,420,000 or USD 0.25 per diluted share a year ago. Adjusted net income was USD 5,957,000 or USD 0.17 per share compared to adjusted net loss of USD 491,000 or USD 0.01 per share a year ago. The increase in Revenue was primarily driven by stronger demand for Infectious Disease products in the first half of the year as a result of a more severe respiratory disease season in 2015 relative to the same period in 2014. Operating activities provided USD 23.3 million of cash and the company purchased property and equipment of USD 7.3 million. For the full year 2015, the company expects effective tax rate to be in the range of 31% to 33%.

Quidel Corp. to Report Q2, 2015 Results on Jul 22, 2015

Quidel Corp. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Jul 22, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $19.04 USD +0.14

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $9.11 USD +0.69
Luminex Corp $17.64 USD +1.13
Nanosphere Inc $1.98 USD +0.08
OraSure Technologies Inc $4.59 USD +0.09
T2 Biosystems Inc $12.12 USD +0.61
View Industry Companies

Industry Analysis


Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.4x
Price/Book 2.9x
Price/Cash Flow 124.3x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at